Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score a data driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Dr Reddy’s Laboratories ( (RDY) ) has shared an announcement.
Dr. Reddy’s Laboratories has been penalized by the Additional Commissioner of Central Tax, Ranga Reddy GST Commissionerate, Hyderabad for an excess refund and unpaid GST on a settlement amount. The order, received on February 1, 2025, includes a penalty of Rs. 1,84,35,58,762. Despite this, Dr. Reddy’s Laboratories stated that there is no material impact on its financials or operations and is considering appealing the decision.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent player in the pharmaceutical industry, primarily involved in the development, manufacture, and marketing of a wide range of pharmaceutical products. The company focuses on providing affordable and innovative medicines across various therapeutic areas and caters to a global market.
YTD Price Performance: -11.81%
Average Trading Volume: 1,574,767
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.73B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.
